Celecoxib upregulates ULBP‑1 expression in lung cancer cells via the JNK/PI3K signaling pathway and increases susceptibility to natural killer cell cytotoxicity

Kim,Jayoung; Noh,Min Hye; Hur,Dae Young; Kim,Bomi; Kim,Yeong Seok; Lee,Hyun-Kyung

doi:10.3892/ol.2020.12142

Celecoxib upregulates ULBP‑1 expression in lung cancer cells via the JNK/PI3K signaling pathway and increases susceptibility to natural killer cell cytotoxicity

Authors:
- Jayoung Kim
- Min Hye Noh
- Dae Young Hur
- Bomi Kim
- Yeong Seok Kim
- Hyun-Kyung Lee
View Affiliations

Affiliations: Department of Medical Science, Pusan National University School of Medicine, Yangsan, South Gyeongsang 50612, Republic of Korea, Department of Anatomy, Inje University College of Medicine, Busan 47396, Republic of Korea, Department of Pathology, Inje University Haewoondae Paik Hospital, Busan 48108, Republic of Korea, Division of Pulmonology, Department of Internal Medicine, Inje University Pusan Paik Hospital, Busan 47396, Republic of Korea
Published online on: September 23, 2020 https://doi.org/10.3892/ol.2020.12142
Article Number: 279
Copyright: © Kim et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer has the highest cancer mortality rate in the world, and effective therapies are still required. Cyclooxygenase‑2 (COX‑2) is highly expressed in numerous types of cancer, and is therefore considered a possible target of cancer treatment. Celecoxib, a selective COX‑2 inhibitor, has binding pockets that interact with COX‑2 and disrupt its enzymatic activities. In addition, celecoxib is able to affect cellular functions in a COX‑2‑independent manner. The present study aimed to investigate if celecoxib affected natural killer (NK) cell receptors and susceptibility to NK cell toxicity. For this purpose, PCR, immunoblotting, flow cytometry analysis and NK cell cytotoxicity assays were performed. The present study revealed that sublethal concentrations of celecoxib increased the expression levels of UL16‑binding protein 1 (ULBP‑1), a natural‑killer group 2 member D (NKG2D) ligand, in lung cancer A549 and H460 cell lines. ULBP‑1 mRNA and protein expression was induced in a dose‑ and time‑dependent manner after celecoxib treatment. Expression levels of other NKG2D ligands, such as ULBP‑2, ULBP‑3, MHC class I‑related chain A (MICA) and MICB did not change considerably compared to ULBP-1 in response to celecoxib treatment. Fluorescence microscopic images revealed abundant ULBP‑1 in the cytoplasm after celecoxib treatment. Both JNK and PI3K may be involved in the induction of ULBP‑1 expression after celecoxib treatment in A549 and H460 cells. In a NK cytotoxicity assay, celecoxib increased the sensitivity to NK cell‑mediated cytotoxicity via interaction with ULBP‑1 in lung cancer cells. Overall, the present results demonstrated that celecoxib treatment induced ULBP‑1 expression in lung cancer cells, thereby increasing their susceptibility to NK cell cytotoxicity. These results suggest that the effects of conventional anticancer therapy may potentially be enhanced by using celecoxib, which targets COX‑2, to enhance the sensitivity of lung cancer cells to NK cell‑mediated cytotoxicity.

View Figures

View References

1	Herbst RS, Heymach JV and Lippman SM: Lung cancer. N Engl J Med. 359:1367–1380. 2008.PubMed/NCBI
2	Bade BC and Dela Cruz CS: Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med. 41:1–24. 2020.PubMed/NCBI
3	Hirsch FR and Lippman SM: Advances in the biology of lung cancer chemoprevention. J Clin Oncol. 23:3186–3197. 2005.PubMed/NCBI
4	Kasymjanova G, Tran AT, Cohen V, Pepe C, Sakr L, Small D, Agulnik JS and Jagoe RT: The use of a standardized Chinese herbal formula in patients with advanced lung cancer: a feasibility study. J Integr Med. 16:390–395. 2018.PubMed/NCBI
5	Dy GK and Adjei AA: Novel targets for lung cancer therapy: Part I. J Clin Oncol. 20:2881–2894. 2002.PubMed/NCBI
6	Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR and Albelda SM: Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: A review. Clin Cancer Res. 11:3974–3986. 2005.PubMed/NCBI
7	Ghosh N, Chaki R, Mandal V and Mandal SC: COX-2 as a target for cancer chemotherapy. Pharmacol Rep. 62:233–244, 2010.7. PubMed/NCBI
8	Gasparini G, Longo R, Sarmiento R and Morabito A: Inhibitors of cyclo-oxygenase 2: A new class of anticancer agents? Lancet Oncol. 4:605–615. 2003.PubMed/NCBI
9	Kalinski P: Regulation of immune responses by prostaglandin E2. J Immunol. 188:21–28. 2012.PubMed/NCBI
10	Williams CS, Mann M and DuBois RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 18:7908–7916. 1999.PubMed/NCBI
11	Liggett JL, Zhang X, Eling TE and Baek SJ: Anti-tumor activity of non-steroidal anti-inflammatory drugs: Cyclooxygenase-independent targets. Cancer Lett. 346:217–224. 2014.PubMed/NCBI
12	Katori M and Majima M: Cyclooxygenase-2: Its rich diversity of roles and possible application of its selective inhibitors. Inflamm Res. 49:367–392. 2000.PubMed/NCBI
13	Gungor H, Ilhan N and Eroksuz H: The effectiveness of cyclooxygenase-2 inhibitors and evaluation of angiogenesis in the model of experimental colorectal cancer. Biomed Pharmacother. 102:221–229. 2018.PubMed/NCBI
14	Huang S and Sinicrope FA: Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. Autophagy. 6:256–269. 2010.PubMed/NCBI
15	Liu M, Li CM, Chen ZF, Ji R, Guo QH, Li Q, Zhang HL and Zhou YN: Celecoxib regulates apoptosis and autophagy via the PI3K/Akt signaling pathway in SGC-7901 gastric cancer cells. Int J Mol Med. 33:1451–1458. 2014.PubMed/NCBI
16	Kim N, Kim CH, Ahn DW, Lee KS, Cho SJ, Park JH, Lee MK, Kim JS, Jung HC and Song IS: Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling. J Gastroenterol Hepatol. 24:480–487. 2009.PubMed/NCBI
17	Dai ZJ, Ma XB, Kang HF, Gao J, Min WL, Guan HT, Diao Y, Lu WF and Wang XJ: Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in vitro and in vivo. Cancer Cell Int. 12:532012.PubMed/NCBI
18	Kim B, Kim J and Kim YS: Celecoxib induces cell death on non-small cell lung cancer cells through endoplasmic reticulum stress. Anat Cell Biol. 50:293–300. 2017.PubMed/NCBI
19	Schellhorn M, Haustein M, Frank M, Linnebacher M and Hinz B: Celecoxib increases lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1. Oncotarget. 6:39342–39356. 2015.PubMed/NCBI
20	Bieniek J, Childress C, Swatski MD and Yang W: COX-2 inhibitors arrest prostate cancer cell cycle progression by down-regulation of kinetochore/centromere proteins. Prostate. 74:999–1011. 2014.PubMed/NCBI
21	Katkoori VR, Manne K, Vital-Reyes VS, Rodríguez-Burford C, Shanmugam C, Sthanam M, Manne U, Chatla C, Abdulkadir SA and Grizzle WE: Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53. Biotech Histochem. 88:38–46. 2013.PubMed/NCBI
22	Grösch S, Maier TJ, Schiffmann S and Geisslinger G: Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 98:736–747. 2006.PubMed/NCBI
23	Wu T, Leng J, Han C and Demetris AJ: The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther. 3:299–307. 2004.PubMed/NCBI
24	Tołoczko-Iwaniuk N, Dziemiańczyk-Pakieła D, Nowaszewska BK, Celińska-Janowicz K and Miltyk W: Celecoxib in cancer therapy and prevention - review. Curr Drug Targets. 20:302–315. 2019.PubMed/NCBI
25	Bryceson YT and Ljunggren HG: Tumor cell recognition by the NK cell activating receptor NKG2D. Eur J Immunol. 38:2957–2961. 2008.PubMed/NCBI
26	Waldhauer I and Steinle A: NK cells and cancer immunosurveillance. Oncogene. 27:5932–5943. 2008.PubMed/NCBI
27	Raulet DH: Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 3:781–790. 2003.PubMed/NCBI
28	Dhar P and Wu JD: NKG2D and its ligands in cancer. Curr Opin Immunol. 51:55–61. 2018.PubMed/NCBI
29	Kim SJ, Ha GH, Bae JH, Kim GR, Son CH, Park YS, Yang K, Oh SO, Kim SH and Kang CD: COX-2- and endoplasmic reticulum stress-independent induction of ULBP-1 and enhancement of sensitivity to NK cell-mediated cytotoxicity by celecoxib in colon cancer cells. Exp Cell Res. 330:451–459. 2015.PubMed/NCBI
30	Reckamp KL: Molecular Targets Beyond the Big 3. Thorac Surg Clin. 30:157–164. 2020.PubMed/NCBI
31	Kyriakis JM and Avruch J: Protein kinase cascades activated by stress and inflammatory cytokines. BioEssays. 18:567–577. 1996.PubMed/NCBI
32	Soriani A, Borrelli C, Ricci B, Molfetta R, Zingoni A, Fionda C, Carnevale S, Abruzzese MP, Petrucci MT, Ricciardi MR, et al: p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells. OncoImmunology. 6:e12645642016.PubMed/NCBI
33	Chen XH, Lu LL, Ke HP, Liu ZC, Wang HF, Wei W, Qi YF, Wang HS, Cai SH and Du J: The TGF-β-induced up-regulation of NKG2DLs requires AKT/GSK-3β-mediated stabilization of SP1. J Cell Mol Med. 21:860–870. 2017.PubMed/NCBI